Data Insights

Tinengotinib by TransThera Sciences (Nanjing) for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Tinengotinib is under clinical development by TransThera Sciences (Nanjing) and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Tinengotinib in Triple-Negative Breast Cancer (TNBC)

Data Insights

Tinengotinib by TransThera Sciences (Nanjing) for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Tinengotinib is under clinical development by TransThera Sciences (Nanjing) and currently in Phase II for Human Epidermal Growth Factor Receptor...

Likelihood of Approval and Phase Transition Success Rate Model - Tinengotinib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Tinengotinib by TransThera Sciences (Nanjing) for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Tinengotinib is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Head And Neck Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Tinengotinib in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Tinengotinib by TransThera Sciences (Nanjing) for Thyroid Cancer: Likelihood of Approval

Tinengotinib is under clinical development by TransThera Sciences (Nanjing) and currently in Phase II for Thyroid Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tinengotinib in Thyroid Cancer

Data Insights

Tinengotinib by TransThera Sciences (Nanjing) for Gallbladder Cancer: Likelihood of Approval

Tinengotinib is under clinical development by TransThera Sciences (Nanjing) and currently in Phase II for Gallbladder Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tinengotinib in Gallbladder Cancer

Data Insights

Tinengotinib by TransThera Sciences (Nanjing) for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Tinengotinib is under clinical development by TransThera Sciences (Nanjing) and currently in Phase III for Bile Duct Cancer (Cholangiocarcinoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - Tinengotinib in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

Tinengotinib by TransThera Sciences (Nanjing) for Solid Tumor: Likelihood of Approval

Tinengotinib is under clinical development by TransThera Sciences (Nanjing) and currently in Phase II for Solid Tumor. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tinengotinib in Solid Tumor

Data Insights

Tinengotinib by TransThera Sciences (Nanjing) for Sarcomas: Likelihood of Approval

Tinengotinib is under clinical development by TransThera Sciences (Nanjing) and currently in Phase II for Sarcomas. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Tinengotinib in Sarcomas

Data Insights

Tinengotinib by TransThera Sciences (Nanjing) for Small-Cell Lung Cancer: Likelihood of Approval

Tinengotinib is under clinical development by TransThera Sciences (Nanjing) and currently in Phase II for Small-Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Tinengotinib in Small-Cell Lung Cancer

Data Insights

Tinengotinib by TransThera Sciences (Nanjing) for Bladder Cancer: Likelihood of Approval

Tinengotinib is under clinical development by TransThera Sciences (Nanjing) and currently in Phase II for Bladder Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tinengotinib in Bladder Cancer

Data Insights

Tinengotinib by TransThera Sciences (Nanjing) for Gastric Cancer: Likelihood of Approval

Tinengotinib is under clinical development by TransThera Sciences (Nanjing) and currently in Phase II for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tinengotinib in Gastric Cancer

Data Insights

Tinengotinib by TransThera Sciences (Nanjing) for Colon Cancer: Likelihood of Approval

Tinengotinib is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Colon Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tinengotinib in Colon Cancer

Data Insights

Tinengotinib by TransThera Sciences (Nanjing) for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Tinengotinib is under clinical development by TransThera Sciences (Nanjing) and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....

Likelihood of Approval and Phase Transition Success Rate Model - Tinengotinib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

Tinengotinib by TransThera Sciences (Nanjing) for Hepatocellular Carcinoma: Likelihood of Approval

Tinengotinib is under clinical development by TransThera Sciences (Nanjing) and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tinengotinib in Hepatocellular Carcinoma

Data Insights

TT-01488 by TransThera Sciences (Nanjing) for Mantle Cell Lymphoma: Likelihood of Approval

TT-01488 is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Mantle Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - TT-01488 in Mantle Cell Lymphoma

Data Insights

TT-01488 by TransThera Sciences (Nanjing) for Follicular Lymphoma: Likelihood of Approval

TT-01488 is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Follicular Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - TT-01488 in Follicular Lymphoma

Data Insights

TT-01488 by TransThera Sciences (Nanjing) for Marginal Zone B-cell Lymphoma: Likelihood of Approval

TT-01488 is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Marginal Zone B-cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - TT-01488 in Marginal Zone B-cell Lymphoma

Data Insights

TT-01488 by TransThera Sciences (Nanjing) for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval

TT-01488 is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - TT-01488 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)

Data Insights

TT-01488 by TransThera Sciences (Nanjing) for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

TT-01488 is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Diffuse Large B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - TT-01488 in Diffuse Large B-Cell Lymphoma

Data Insights

TT-01488 by TransThera Sciences (Nanjing) for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

TT-01488 is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - TT-01488 in Chronic Lymphocytic Leukemia (CLL)